Products for Research Use Only

BM213

CAT: 0804-HY-145237-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145237-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury[1].
CAS Number
2891606-02-1
UNSPSC
12352209
Target
Apoptosis; Complement System; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bm213.html
Purity
99.81
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
OC([C@@H](NC([C@@H](C)NC([C@H](C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@@H]1CCCN1C([C@@H](NC([C@H](CC2=CC=CC=C2)NC(C)=O)=O)CCCCN[H])=O)=O)=O)=O)=O)=O)CCCNC(N)=N)=O
Molecular Formula
C43H70N12O10
Molecular Weight
915.09
References & Citations
[1]Zhang M, et al. 13-methylpalmatine alleviates myocardial ischemia/reperfusion injury by potentially targeting the C5a-C5aR1 axis to inhibit neutrophil extracellular trap formation. Redox Biol. 2025 Aug 5;86:103802. |[2]Gorman DM, et al. Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. J Med Chem. 2021 Nov 25;64 (22) :16598-16608.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported